Related Experiment Videos
Ras induces NBT-II epithelial cell scattering through the coordinate activities of Rac and MAPK pathways
Natacha Edme1, Julian Downward, Jean-Paul Thiery
1Laboratoire de Régulations Cellulaires et Oncogénése UMR146, Institut Curie Section de Recherche, Centre Universitaire Paris-Sud, 91405 Orsay, France.
Journal of Cell Science
|June 5, 2002
Summary
Ras signaling in NBT-II cells drives cell dissociation and migration during epithelial-mesenchymal transition (EMT). The study identifies Raf/MAPK and Rac pathways as key mediators of these EMT processes.
Area of Science:
- Cell Biology
- Molecular Biology
- Cancer Research
Background:
- Epithelial-mesenchymal transition (EMT) involves cell dissociation and migration.
- Ras signaling is crucial for EGF-induced EMT in NBT-II rat carcinoma cells.
Purpose of the Study:
- To identify Ras downstream targets responsible for cell dissociation and migration during EMT.
- To elucidate the specific roles of Raf/MAPK and Rac pathways in Ras-mediated EMT.
Main Methods:
- Overexpression of activated Ras pathway components (c-Raf, MEK1, PI3K, RalA/B).
- Use of specific inhibitors (PD098059, LY294002) and Ras mutants (RasV12S35, RasV12E38).
- Assessment of cell dissociation via desmosome loss and cell migration using dominant-negative Rac1 (Rac1N17).
Main Results:
- Activated c-Raf and MEK1 induced cell dissociation by disrupting desmosomes.
- MEK1 inhibition blocked EGF- and Ras-induced cell dispersion; PI3K inhibition had no effect.
- Specific Ras mutants targeting Raf induced dissociation, while PI3K/RalGDS mutants did not.
- MEK1 alone did not promote motility, but Ras mutants and Rac activation did.
- Rac1 is essential for EGF-induced cell migration, and its activation correlates with motility.
Conclusions:
- Ras mediates NBT-II cell scattering through coordinated activation of Rac and the Raf/MAPK pathway.
- Distinct Ras effectors regulate cell dissociation (Raf/MAPK) and cell migration (Rac).
- Understanding these pathways is key for targeting EMT in cancer progression.